rhPTH（1-34） 28.2μg
Biologic
rhPTH（1-34） 28.2μg is one of 38 biologic programs targeting Postmenopausal Osteoporosis. It is currently in development.
1
Indications
1
Total Trials
0
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
53 competitors in Postmenopausal Osteoporosis
#DrugCompanyPhaseTrials
1Zometa
PfizerApproved
Evista
Eli LillyApproved
Forteo
AAlmaject
Approved
Calciferol
Alnylam PharmaceuticalsApproved
Estrace
Novo NordiskApproved
Boniva
CConrado Roberto Hoffmann Filho
Approved
Epsom Salt
FFresenius Kabi Oncology Ltd.
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Estradiol Valerate
BayerApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for rhPTH（1-34） 28.2μg. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]